A Phase 3 interventional study of Olokizumab 64mg q4w and Olokizumab 64mg q2w in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 203 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2016.
This study's enrollment of 1,648 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under R-Pharm International, LLC, one of the names counted as R-Pharm. Under that name alone:
R-Pharm International, LLC is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
R-Pharm has 5 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate (MTX).
The primary objective of this study was to evaluate the efficacy of OKZ 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active RA inadequately controlled by MTX therapy.
The secondary objective was to evaluate the efficacy of OKZ relative to adalimumab in subjects with moderately to severely active RA inadequately controlled by MTX therapy.
The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ in subjects with moderately to severely active RA who had responded inadequately to MTX. The primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period.
This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44. Subjects were assessed for eligibility to enter the study during the 4-week Screening Period. A total of 1575 subjects were planned to be randomly assigned to 1 of 4 treatment groups in a 2:2:2:1 ratio (450, 450, 450, and 225 subjects per group, respectively):
Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX with a stable route of administration. Concomitant treatment with folic acid was required for all subjects. The last dose of study treatment (OKZ, adalimumab, or placebo) was at Week 22 in all groups.
Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every 2 weeks through Week 24 for response and safety assessments.
At Week 14, subjects who had not improved by at least 20% in both swollen and tender joint counts were classified as nonresponders and were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment.
After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment.
Subjects who had discontinued randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continue with the scheduled study visits.
Adverse events (AEs) were assessed throughout the study (starting when the subject signed the informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study by an independent Data Safety Monitoring Board and potential major adverse cardiac events were evaluated by an independent Cardiovascular Adjudication Committee.
The study was conducted at 208 sites across 18 countries globally (in US, European Union (EU),United Kingdom (UK), Russian Federation, Asia, Latin America).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have moderately to severely active RA disease as defined by all of the following:
Exclusion Criteria:
Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):
Subjects with:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
Drug: Olokizumab 64mg q4w · Drug: Placebo q2w
Olokizumab 64mg subcutaneous q2w + Methotrexate 64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)
Drug: Olokizumab 64mg q2w
Adalimumab 40mg q2w subcutaneous + Methotrexate Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)
Drug: Adalimumab 40mg q2w
Placebo q2w subcutaneous + Methotrexate Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)
Drug: Placebo q2w
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
0.4 or 0.8 mL prefilled, single-dose syringe
Also known as: Humira
sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint served to demonstrate that the efficacy of OKZ was superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab
A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.This endpoint served to demonstrate that the efficacy of OKZ was non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Percentage of Subjects Achieving Low Disease Activity
Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12
Time frame: at Week 12
Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab
Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint
Time frame: at Week 12
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).
Time frame: Baseline to Week 12
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 24
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24
Time frame: at Week 24
Enrollment was conducted at 208 clinical sites across 18 countries (US,EU,UK, Russian Federation, Asia, Latin America). 3359 subjects were screened and 1648 subjects were enrolled (randomized). A total of 1645 subjects were treated, and 1483 subjects completed the study. A total of 1648 subjects were analyzed for efficacy in the ITT Population and 1645 subjects were analyzed for safety in the Safety Population.
| Milestone | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Started | 479 | 464 | 462 | 243 |
| Completed | 443 | 421 | 412 | 207 |
| Not completed | 36 | 43 | 50 | 36 |
| Withdrew: Death | 2 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 7 | 4 | 6 |
| Withdrew: Withdrawal by subject | 25 | 31 | 37 | 25 |
| Withdrew: Violation of eligibility criteria | 0 | 0 | 1 | 1 |
| Withdrew: Personal reasons | 0 | 0 | 0 | 1 |
| Withdrew: The subject was early discontinued due to lab adverse event as per investigator's decision | 1 | 0 | 0 | 0 |
| Withdrew: Use of prohibited medication | 0 | 0 | 1 | 0 |
| Withdrew: Subject didn't completed visits schedule after serious adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Positive quantiferon testing, patient was not taken prophylactic medication | 1 | 0 | 0 | 0 |
| Withdrew: Investigator's decision (adverse event) | 0 | 1 | 0 | 0 |
| Withdrew: Inadequately enrolled | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by pi's decision | 0 | 1 | 0 | 0 |
| Withdrew: Subject did not attend treatment period visits due to misunderstanding of protocol | 1 | 0 | 1 | 0 |
| Withdrew: Subject met permanent ip discontinuation criteria, did not agree for treatment period visits | 0 | 0 | 1 | 0 |
| Withdrew: Investigator recorded as sponsor's decision - decreased lymphocyte level | 1 | 0 | 0 | 0 |
| Withdrew: Study treatment was terminated at the site | 0 | 0 | 1 | 0 |
| Withdrew: Subject taken out of study due to sponsor investigating investigational product. | 1 | 0 | 0 | 0 |
| Withdrew: Inadequately enrolled patient refused to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy per pi | 0 | 0 | 0 | 1 |
| Withdrew: Patient had an upper respiratory infection and took medication that was not allowed | 1 | 0 | 0 | 0 |
| Withdrew: Investigator recorded as adverse event | 1 | 0 | 2 | 0 |
The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint served to demonstrate that the efficacy of OKZ was superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 342 | 326 | 309 | 108 |
A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.This endpoint served to demonstrate that the efficacy of OKZ was non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | 342 | 326 | 309 | 108 |
Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects Achieving Low Disease Activity | 220 | 210 | 177 | 31 |
Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | 220 | 210 | 177 | 31 |
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).
| score on a scale | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.60 ± 0.028 | -0.65 ± 0.030 | -0.61 ± 0.029 | -0.42 ± 0.039 |
Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 240 | 234 | 214 | 55 |
Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24
| Participants | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 58 | 51 | 60 | 10 |
Collected over All AEs were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment, up to approximately 44 weeks. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | 2/477 (0.4%) | 20/477 (4.2%) | 177/477 (37.1%) |
| Arm 2: Olokizumab q2w + Methotrexate | 3/463 (0.6%) | 22/463 (4.8%) | 183/463 (39.5%) |
| Arm 3: Adalimumab q2w + Methotrexate | 1/462 (0.2%) | 26/462 (5.6%) | 129/462 (27.9%) |
| Arm 4: Placebo q2w + Methotrexate | 1/243 (0.4%) | 12/243 (4.9%) | 71/243 (29.2%) |
| Event | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/477 | 1/463 | 6/462 | 0/243 |
| UrosepsisInfections and infestations | 0/477 | 0/463 | 2/462 | 2/243 |
| SepsisInfections and infestations | 1/477 | 1/463 | 2/462 | 0/243 |
| Urinary tract infectionInfections and infestations | 0/477 | 0/463 | 2/462 | 0/243 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/477 | 0/463 | 2/462 | 0/243 |
| Transaminases increasedInvestigations | 0/477 | 2/463 | 0/462 | 1/243 |
| CellulitisInfections and infestations | 2/477 | 0/463 | 0/462 | 0/243 |
| Alanine aminotransferase increasedInvestigations | 2/477 | 1/463 | 1/462 | 0/243 |
| Abscess limbInfections and infestations | 0/477 | 0/463 | 0/462 | 1/243 |
| KeratouveitisInfections and infestations | 0/477 | 0/463 | 0/462 | 1/243 |
| Event | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 53/477 | 41/463 | 9/462 | 4/243 |
| NasopharyngitisInfections and infestations | 26/477 | 29/463 | 29/462 | 18/243 |
| Upper respiratory tract infectionInfections and infestations | 29/477 | 28/463 | 26/462 | 16/243 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 20/477 | 29/463 | 6/462 | 3/243 |
| HypertensionVascular disorders | 27/477 | 25/463 | 13/462 | 8/243 |
| DyslipidaemiaMetabolism and nutrition disorders | 15/477 | 25/463 | 4/462 | 4/243 |
| Aspartate aminotransferase increasedInvestigations | 24/477 | 23/463 | 8/462 | 2/243 |
| HeadacheNervous system disorders | 11/477 | 10/463 | 14/462 | 12/243 |
| HyperlipidaemiaMetabolism and nutrition disorders | 10/477 | 22/463 | 5/462 | 2/243 |
| BronchitisInfections and infestations | 10/477 | 12/463 | 11/462 | 11/243 |
| Age, Categorical(Participants) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 389 | 379 | 367 | 192 | 1327 |
| >=65 years | 90 | 85 | 95 | 51 | 321 |
| Age, Continuous(years) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| Mean | 53.7 ± 12.09 | 53.3 ± 11.92 | 54.3 ± 12.32 | 54.7 ± 11.85 | 53.9 ± 12.07 |
| Sex: Female, Male(Participants) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| Female | 378 | 352 | 363 | 190 | 1283 |
| Male | 101 | 112 | 99 | 53 | 365 |
| Race/Ethnicity, Customized(Participants) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| Asian | 6 | 10 | 4 | 5 | 25 |
| Black or African American | 15 | 20 | 23 | 11 | 69 |
| White | 406 | 382 | 385 | 203 | 1376 |
| Other/Mixed | 52 | 52 | 50 | 24 | 178 |
| Region of Enrollment(participants) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| Colombia | 18 | 17 | 16 | 8 | 59 |
| Argentina | 44 | 42 | 43 | 24 | 153 |
| Romania | 0 | 0 | 1 | 0 | 1 |
| Hungary | 15 | 13 | 13 | 10 | 51 |
| United States | 75 | 71 | 72 | 39 | 257 |
| Czechia | 58 | 50 | 51 | 30 | 189 |
| United Kingdom | 3 | 1 | 6 | 1 | 11 |
| Russia | 20 | 21 | 25 | 11 | 77 |
| Latvia | 1 | 3 | 0 | 0 | 4 |
| South Korea | 2 | 4 | 1 | 4 | 11 |
| Taiwan | 2 | 3 | 2 | 1 | 8 |
| Brazil | 33 | 33 | 30 | 16 | 112 |
| Poland | 90 | 85 | 87 | 46 | 308 |
| Mexico | 63 | 63 | 59 | 30 | 215 |
| Bulgaria | 18 | 20 | 19 | 8 | 65 |
| Lithuania | 22 | 22 | 22 | 8 | 74 |
| Germany | 11 | 13 | 10 | 6 | 40 |
| Estonia | 4 | 3 | 5 | 1 | 13 |
| Body Mass Index (BMI)(kg/m^2) | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|---|
| Mean | 28.654 (16.96 to 52.74) | 28.656 (17.04 to 62.22) | 28.532 (17.48 to 56.52) | 28.573 (15.62 to 55.83) | 28.609 (15.62 to 62.22) |
Showing the first 100 of 203 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Aug 2019, 37 months.
Results were first posted in Apr 2021, 1 year 8 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 37 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab